Chang, Patrick C
Yuan, Xuegang
Zampieri, Alexandre
Towns, Chloe
Yoo, Sang Pil
Engstrom, Claire
Tsai, Steven
Robles, Christopher R.
Zhu, Yuhua
Lopez, Shawn
Montel-Hagen, Amelie
Seet, Christopher S.
Crooks, Gay M. http://orcid.org/0000-0002-2488-8468
Funding for this research was provided by:
California Institute for Regenerative Medicine (DISC2-10134)
Pluto Immunotherapeutics, Inc.
U.S. Department of Health & Human Services | NIH | National Cancer Institute (F31CA239555, K08CA235525)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (T32HL086345)
UC | UCLA | Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles (Fellowship, Fellowship, Fellowship)
V Foundation for Cancer Research (Scholar Award)
Article History
Received: 8 September 2022
Accepted: 25 October 2023
First Online: 7 December 2023
Competing interests
: Pluto Immunotherapeutics is supporting further preclinical research on the ATO system at UCLA through a sponsored research agreement with G.M.C. as principal investigator. A.M.-H., G.M.C. and C.S.S. are co-founders of Pluto Immunotherapeutics, which holds certain rights relating to the ATO system. G.M.C. and C.S.S. are consultants to, and A.M.-H. is a current employee of, Pluto Immunotherapeutics. The other authors declare no competing interests.